AstraZeneca(US:AZN) 国泰海通证券研究·2026-02-03 14:00Core Insights - AstraZeneca announced a plan to invest $15 billion in China, primarily focused on cell therapy and radiolabeled conjugates during the visit of the UK Prime Minister [1][2] - This investment aims to leverage China's scientific capabilities and advanced manufacturing to provide cutting-edge treatment solutions for patients globally [1] Investment Details - The $15 billion investment will significantly enhance AstraZeneca's capabilities in cell therapy and radiolabeled conjugates, addressing cancer, blood diseases, and autoimmune diseases [2] - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, with collaborations with leading biotech companies to bring Chinese innovations to the world [2] - Specific uses of the investment include: 1. Establishing global strategic R&D centers in Beijing and Shanghai 2. Expanding existing manufacturing bases in Wuxi, Taizhou, Qingdao, and Beijing, along with setting up new facilities 3. Increasing the skilled workforce in China to over 20,000 employees [2] Market Implications - This investment reflects multinational corporations' growing interest and recognition of local R&D capabilities and the Chinese market, driven by the ongoing validation of China's engineering talent and biopharmaceutical capabilities [3]